Spine-Rad™ Cement
Tumors in bone (primary and metastatic), initially targeting the spine
Key Facts
About Bone-Rad
Bone-Rad Therapeutics is a development-stage biotech company pioneering a novel treatment for bone tumors, particularly spinal metastases. Its lead product, Spine-Rad™ Cement, integrates a radioactive isotope (Phosphorus-32) into standard bone cement to deliver localized radiation while mechanically reinforcing the bone, potentially improving efficacy and patient quality of life. Founded in 2016 based on technology licensed from the University of California in 2010, the company is currently in a start-up funding phase, seeking investment to advance its platform. It targets a significant market opportunity driven by an aging population and the high prevalence of spinal involvement in metastatic cancer.
View full company profile